ReviewJournal of gastroenterology2007
Helicobacter pylori: present status and future prospects in Japan.
Review in Journal of gastroenterology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 170 citations in OpenAlex.
- Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy: a systematic review.Journal of gastroenterology · 2009Pooled it
- First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.World journal of gastroenterology · 2015Trial
- Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS).BMC gastroenterology · 2012Trial
- Article
- Pattern of Primary Resistance ofChildren (Basel, Switzerland) · 2023Article
- Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol.BMC gastroenterology · 2023Article
- Article
- Genistein attenuated gastric inflammation and apoptosis in Helicobacter pylori-induced gastropathy in rats.BMC gastroenterology · 2020Article
- Comparison of clinical symptoms afterNew microbes and new infections · 2020Article
- Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori.Cancers · 2019Article
- Identification of key miRNAs and genes associated with stomach adenocarcinoma from The Cancer Genome Atlas database.FEBS open bio · 2018Article
- The Bifunctional Enzyme SpoT Is Involved in the Clarithromycin Tolerance of Helicobacter pylori by Upregulating the Transporters HP0939, HP1017, HP0497, and HP0471.Antimicrobial agents and chemotherapy · 2017Article
- Changing epidemiology of Helicobacter pylori in Japan.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2017Review
- The Impact ofFrontiers in microbiology · 2017Article
- Helicobacter pylori outer membrane protein and virulence marker differences in expatriate patients.Epidemiology and infection · 2016Article
- Effect ofExperimental and therapeutic medicine · 2016Article
- Multidrug Efflux Systems in Microaerobic and Anaerobic Bacteria.Antibiotics (Basel, Switzerland) · 2015Review
- Nordihydroguaiaretic Acid Disrupts the Antioxidant Ability of Helicobacter pylori through the Repression of SodB Activity In Vitro.BioMed research international · 2015Article
- Seroprevalence of helicobacter pylori in human immunodeficiency virus-positive Patients and it's correlation with CD4(+) Lymphocyte Count.Nigerian medical journal : journal of the Nigeria Medical Association · 2014Article
- Do we need to eradicate Helicobacter pylori in patients with GORD?United European gastroenterology journal · 2013Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of Helicobacter pylori has already changed the natural history of peptic ulcer disease, with most patients being cured at their first presentation. Similarly, the incidence of gastric cancer and other diseases related to H. pylori are likely to be greatly reduced in the near future. Isolation of the spiral intragastric bacterium H. pylori totally reversed the false dogma that the stomach was sterile, and it taught us that chronic infectious disease can still exist in modern society. Helicobacter pylori's unique location, persistence, and evasion of the immune system offer important insights into the pathophysiology of the gut. Also, the fact that it was overlooked for so long encourages us to think "outside the box" when investigating other diseases with obscure etiologies. We should consider such provocative scientific ideas as bridges to the future disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.